SRB19

N/A

Report date: 2024/08/01 10:15:40

Base Information

Drug NameSRB19

Drug Alias NameSRB19SRB-19

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-Receptor tyrosine-protein kinase erbB-3Anti-Epidermal growth factor receptor erbB1

TargetsReceptor tyrosine-protein kinase erbB-3Epidermal growth factor receptor erbB1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSunRock Biopharma SL

China Registration ClassN/A

Develop Information

Active CompaniesSunRock Biopharma SL

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A